Анализа корелације нивоа цитокина у серуму и имунолошких фактора упале код циротичне портне хипертензије
Нивои цитокина у серуму и имуни инфламаторни фактори код циротичне порталне хипертензије
Sažetak
Objective: To investigate alterations in immune inflammatory factors and variables including procalcitonin (PCT), prostaglandin E (PGE), and serum C-reactive protein (CRP) in individuals with cirrhotic portal hypertension.
Methods: From March 2020 to March 2025, 81 patients with cirrhotic portal hypertension and 50 healthy volunteers were hospitalized to our hospital. These people were divided into two groups: the portal hypertension group and the control group. Aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL), alanine aminotransferase (ALT), and portal vein inner diameter (Pvd) were measured. Serum cytokines such CRP, PCT, and PGE were measured, as well as CD4+/CD8+ T cell and CD3+, CD4+, and CD8+ T lymphocyte percentages.
Results: The group with portal hypertension had considerably lower ALB than the control group (P<0.05), whereas indicators including ALT, AST, TBIL, and Dpv were significantly higher in the portal hypertension group than in the control group (P<0.05). While cytokine markers including CRP, PCT, and PGE were higher in the portal hypertension group than in the control group (P<0.05), the numbers of CD3+ and CD4+ T lymphocyte subsets and CD4+/CD8+ T lymphocytes were considerably lower in the portal hypertension group. With increasing liver function classification, the proportions of CD3+ and CD4+ T lymphocyte subsets and CD4+/CD8+ T lymphocytes in patients decreased. However, there was a statistically significant (P<0.05) increase in the levels of serum PCT, PGE, and CRP. Spearman correlation analysis revealed that liver function classification was negatively correlated with immune indicators CRP, PCT, and PGE levels were favorably connected with CD4+ and CD4+/CD8+ (P<0.05) values. Dpv was shown to have a negative association with CD4+/CD8+ T cells and a positive correlation with PCT and PGE levels (P<0.05) according to Pearson correlation analysis.
Conclusion: Patients with cirrhotic portal hypertension may experience immune dysfunction and cytokine disorders. These changes are related to liver function and portal vein pressure and can be used as reference indicators for evaluating a patient's condition in clinical practice.
Reference
2.Turco L, Reiberger T, Vitale G, La Mura V. Carvedilol as the new nonselective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int. 2023 Jun;43(6):1183-1194. doi: 10.1111/liv.15559. Epub 2023 Apr 17. PMID: 36897563.
3.Guixé-Muntet S, Quesada-Vázquez S, Gracia-Sancho J. Pathophysiology and therapeutic options for cirrhotic portal hypertension. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):646-663. doi: 10.1016/S2468-1253(23)00438-7. Epub 2024 Apr 17. PMID: 38642564.
4.Tonon M, Piano S. Cirrhosis and Portal Hypertension: How Do We Deal with Ascites and Its Consequences. Med Clin North Am. 2023 May;107(3):505-516. doi: 10.1016/j.mcna.2022.12.004. Epub 2023 Feb 20. PMID: 37001950.
5.Jothimani D, Rela M, Kamath PS. Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices? Med Clin North Am. 2023 May;107(3):491-504. doi: 10.1016/j.mcna.2023.01.002. Epub 2023 Feb 20. PMID: 37001949.
6.Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology. 2023 Dec 1;78(6):1896-1906. doi: 10.1097/HEP.0000000000000278. Epub 2023 Jan 3. PMID: 37013380.
7.Reiberger T. The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis. Hepatol Commun. 2022 May;6(5):950-964. doi: 10.1002/hep4.1855. Epub 2021 Dec 14. PMID: 34904404; PMCID: PMC9035575.
8.Kristensen H, Kimer N, Møller S. Indications and methods for measuring portal hypertension in cirrhosis. Scand J Gastroenterol. 2022 Oct;57(10):1149-1157. doi: 10.1080/00365521.2022.2065889. Epub 2022 May 6. PMID: 35514215.
9.Terbah R, Testro A, Gow P, Majumdar A, Sinclair M. Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis-Pathogenesis, Implications and Therapeutic Opportunities. Nutrients. 2023 Dec 21;16(1):35. doi: 10.3390/nu16010035. PMID: 38201864; PMCID: PMC10780673.
10.Li X, Kang N, Qi X, Huang Y. Artificial intelligence in the diagnosis of cirrhosis and portal hypertension. J Med Ultrason (2001). 2022 Jul;49(3):371-379. doi: 10.1007/s10396-021-01153-8. Epub 2021 Nov 17. PMID: 34787742.
11.Brown RS Jr, Brown KA, Flamm S, Bejarano RE, Rahimi RS, Singal AK, Rockey DC. Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives. Hepatol Commun. 2025 Apr 3;9(4):e0682. doi: 10.1097/HC9.0000000000000682. PMID: 40178492; PMCID: PMC11970884.
12.Alvarado-Tapias E, Brujats A, Puente A, Ardevol A, Rodriguez-Arias A, Fajardo J, Pavel O, Garcia-Guix M, Aracil C, Poca M, Cuyàs B, Cantó E, Montañés R, Garcia-Osuna A, Escorsell À, Torras X, Villanueva C. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial. Hepatology. 2025 Jul 1;82(1):140-154. doi: 10.1097/HEP.0000000000001148. Epub 2024 Nov 7. PMID: 39509369.
13.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
14.Hasan I. Cirrhosis Management: Utilization and Optimizing Non-Invasive Tests in Portal Hypertension. Acta Med Indones. 2024 Jul;56(3):273-275. PMID: 39463106.
15.Wang C, Huang Y, Liu C, Liu F, Hu X, Kuang X, An W, Liu C, Liu Y, Liu S, He R, Wang H, Qi X. Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model. Radiology. 2023 Apr;307(2):e221648. doi: 10.1148/radiol.221648. Epub 2023 Jan 31. Erratum in: Radiology. 2023 Jul;308(1):e239019. doi: 10.1148/radiol.239019. PMID: 36719293.
16.Guo Y, Ma X, Nie Y, Kostallari E, Gao J. Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension. Front Immunol. 2023 Mar 9;14:1174562. doi: 10.3389/fimmu.2023.1174562. PMID: 36969230; PMCID: PMC10034766.
17.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
18.Shukla A, Rockey DC, Kamath PS, Kleiner DE, Singh A, Vaidya A, Koshy A, Goel A, Dökmeci AK, Meena B, Philips CA, Sharma CB, Payawal DA, Kim DJ, Lo GH, Han G, Qureshi H, Wanless IR, Jia J, Sollano JD, Al Mahtab M, Muthiah MD, Sonderup MW, Nahum MS, Merican MIB, Ormeci N, Kawada N, Reddy R, Dhiman RK, Gani R, Hameed SS, Harindranath S, Jafri W, Qi X, Chawla YK, Furuichi Y, Zheng MH, Sarin SK. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management. Hepatol Int. 2024 Dec;18(6):1684-1711. doi: 10.1007/s12072-024-10739-6. Epub 2024 Nov 15. PMID: 39546143.
19.Juneja P, Tripathi DM, Kaur S. Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2022 May 1;322(5):G473-G479. doi: 10.1152/ajpgi.00271.2021. Epub 2022 Feb 23. PMID: 35195034.
20.Vandenberk B, Altieri MH, Liu H, Raj SR, Lee SS. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2023 Feb;57(3):290-303. doi: 10.1111/apt.17368. Epub 2022 Dec 26. PMID: 36571829.
21.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
22.Gillespie SL, Hanrahan TP, Rockey DC, Majumdar A, Hayes PC. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. Aliment Pharmacol Ther. 2023 Mar;57(5):454-463. doi: 10.1111/apt.17380. Epub 2023 Jan 24. PMID: 36691947.
23.Villanueva C, Tripathi D. Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: However, not so fast! Liver Int. 2023 Jun;43(6):1154-1156. doi: 10.1111/liv.15582. PMID: 37166136.
24.Celsa C, Veneziano M, Di Giorgio FM, Cannova S, Lombardo A, Errigo E, Landro G, Simone F, Sinagra E, Calvaruso V. Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review. Medicina (Kaunas). 2024 Apr 24;60(5):690. doi: 10.3390/medicina60050690. PMID: 38792873; PMCID: PMC11123262.
25.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
26.Li R, Liu HS, Chen Y. [Recent Research Advance to Differentiate Portal Hypertension Associated with Primary Myelofibrosis and Cirrhosis --Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Apr;31(2):598-601. Chinese. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.043. PMID: 37096541.
27.Chang G, Sun J, Li J, Li T. Effect of Probiotics on Portal Hypertension (PH) with Cirrhosis: A Systematic Review and Meta-Analysis. Clin Res Hepatol Gastroenterol. 2024 Jun;48(6):102361. doi: 10.1016/j.clinre.2024.102361. Epub 2024 May 1. PMID: 38701917.
28.Albillos A, Bañares R, Hernández-Gea V; en representación del grupo español de Consenso en Hipertensión Portal. Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd). Gastroenterol Hepatol. 2025 Jan;48(1):502208. English, Spanish. doi: 10.1016/j.gastrohep.2024.502208. Epub 2024 Sep 30. PMID: 39756832.
29.Lan T, Li S, Yu H, Kostallari E, Gao J. Editorial: Community series in hepatic immune response underlying liver cirrhosis and portal hypertension, volume II. Front Immunol. 2023 Oct 11;14:1305666. doi: 10.3389/fimmu.2023.1305666. PMID: 37901235; PMCID: PMC10600445.
30.Manzano-Nunez R, Rivera-Esteban J, Comas M, Angel M, Flores V, Bañares J, Ciudin A, Vilallonga R, Pericas JM. Outcomes of Patients with Severe Obesity and Cirrhosis with Portal Hypertension Undergoing Bariatric Surgery: a Systematic Review. Obes Surg. 2023 Jan;33(1):224-233. doi: 10.1007/s11695-022-06362-9. Epub 2022 Nov 24. PMID: 36422758.
31.Ibrahim RS, El-Mezayen NS, El-Banna AA. Alleviation of liver cirrhosis and associated portal-hypertension by Astragalus species in relation to their UPLC-MS/MS metabolic profiles: a mechanistic study. Sci Rep. 2022 Jul 13;12(1):11884. doi: 10.1038/s41598-022-15958-1. PMID: 35831335; PMCID: PMC9279505.
32.Vairappan B, Wright G, M S, Ravikumar TS. Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF. Eur J Pharmacol. 2023 Nov 5;958:176010. doi: 10.1016/j.ejphar.2023.176010. Epub 2023 Aug 25. PMID: 37634841.
33.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
34.Tapper EB, Ospina E, Salim N, Chen X, Nikirk S. Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: The Mi-Kristal trial. Hepatology. 2023 Oct 1;78(4):1159-1167. doi: 10.1097/HEP.0000000000000408. Epub 2023 Apr 18. PMID: 37066820; PMCID: PMC10524505.
35.Duursma SS, Verkade HJ, Bodewes FAJA. Cirrhosis and Portal Hypertension in Compound Heterozygous People With Cystic Fibrosis Harboring One F508del CFTR Gene Mutation. Gastroenterology. 2022 Oct;163(4):1098-1100. doi: 10.1053/j.gastro.2022.06.019. Epub 2022 Jun 10. PMID: 35697137.
36.Kotani K, Enomoto M, Uchida-Kobayashi S, Tamori A, Yukawa-Muto Y, Odagiri N, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Kageyama K, Yamamoto A, Yoshida A, Higashiyama S, Kawabe J, Kawada N. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis. J Gastroenterol. 2023 Apr;58(4):394-404. doi: 10.1007/s00535-023-01963-2. Epub 2023 Feb 2. PMID: 36729172; PMCID: PMC10049944.
37.Miceli G, Calvaruso V, Casuccio A, Pennisi G, Licata M, Pintus C, Basso MG, Velardo M, Daidone M, Amodio E, Petta S, Simone F, Cabibbo G, Di Raimondo D, Craxì A, Pinto A, Tuttolomondo A. Heart rate variability is associated with disease severity and portal hypertension in cirrhosis. Hepatol Commun. 2023 Feb 9;7(3):e0050. doi: 10.1097/HC9.0000000000000050. PMID: 36757394; PMCID: PMC9916116.
38.Zhu CP, Liu SQ, Wang KQ, Xiong HL, Aristu-Zabalza P, Boyer-Díaz Z, Feng JF, Song SH, Luo C, Chen WS, Zhang X, Dong WH, Gracia-Sancho J, Xie WF. Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension. Gastroenterology. 2024 Oct;167(5):993-1007. doi: 10.1053/j.gastro.2024.06.007. Epub 2024 Jun 19. PMID: 38906512.
Sva prava zadržana (c) 2025 Yafeng Yu, Zhiqiong Lan, Zhiren Huang, Lingqin Hu
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.